Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors | MicrobiomeTrials← Back to trialsNCT04665739
Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2023-02-03Est. Completion: 2027-07-01
Enrollment target: 70 participants Locations- University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
- Tower Cancer Research Foundation, Beverly Hills, California, United States
- Loma Linda University Medical Center, Loma Linda, California, United States
- Cedars-Sinai Medical Center, Los Angeles, California, United States
- UCSF Medical Center-Mission Bay, San Francisco, California, United States
- Torrance Memorial Physician Network - Cancer Care, Torrance, California, United States
- MedStar Georgetown University Hospital, Washington D.C., District of Columbia, United States
- UM Sylvester Comprehensive Cancer Center at Aventura, Aventura, Florida, United States
- UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida, United States
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach, Florida, United States
- University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States
- UM Sylvester Comprehensive Cancer Center at Plantation, Plantation, Florida, United States
- University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
Other microbiome trials you might be interested in
CancerSolid TumorMelanomaCarcinomaSarcomaLung CancerProstate CancerBreast CancerColo-rectal CancerUterine CancerPancreatic CancerGastric CancerEsophageal CancerThyroid CancerOvarian CancerKidney CancerHead and Neck Cancer
The goal of this clinical trial is to test the safety and efficacy of KVA12123 alone or combined with pembrolizumab in p…
Santa Monica, United States
UC Comprehensive Cancer Center at Silver Cross, New Lenox, Illinois, United StatesUniversity of Chicago Medicine-Orland Park, Orland Park, Illinois, United StatesUI Health Care Mission Cancer and Blood - Ankeny Clinic, Ankeny, Iowa, United StatesIowa Methodist Medical Center, Des Moines, Iowa, United StatesUI Health Care Mission Cancer and Blood - Des Moines Clinic, Des Moines, Iowa, United StatesDana-Farber Cancer Institute, Boston, Massachusetts, United StatesMayo Clinic in Rochester, Rochester, Minnesota, United StatesMissouri Baptist Medical Center, St Louis, Missouri, United StatesDuke University Medical Center, Durham, North Carolina, United StatesCase Western Reserve University, Cleveland, Ohio, United StatesOhio State University Comprehensive Cancer Center, Columbus, Ohio, United StatesFox Chase Cancer Center, Philadelphia, Pennsylvania, United StatesTemple University Hospital, Philadelphia, Pennsylvania, United StatesUniversity of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United StatesVanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United StatesHuntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United StatesCompleted Oct 16, 2025
Muscle-Invasive Bladder CarcinomaGastroesophageal AdenocarcinomaMelanomaNon-small Cell Lung Cancer
This is a phase 1 clinical trial to evaluate the safety, feasibility and immunogenicity of a personalized cancer vaccine…
St Louis, United StatesEst. completion Jan 31, 2030